CAR T-cell therapy promising in young adults with B-ALL

Young adults with B-ALL may be at higher risk of adverse events from the anti-CD19 CAR T-cell therapy tisagenlecleucel than children. Dr Susana Rives (Hospital Sant Joan de Déu de Barcelona, Spain) and colleagues compared the safety and efficacy of tisagenlecleucel in 20 young adults (18-25 y) and 84 children (<18 y) treated in the ELIANA and ENSIGN trials. ORR was 70% in young adults and 80% in children, and median duration of response was not reached in either group. The safety profile was similar in both groups. Cytokine release syndrome of grade 3 or higher occurred at similar rates in both groups, and did not lead to fatalities. No cerebral edema was reported.

Visit the EHA Learning Center to view the abstract.

Last Updated on Friday 03 August 2018.